Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Oct 13, 2023 4:03pm
629 Views
Post# 35682914

Outstanding Encouraging Results...

Outstanding Encouraging Results...Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N-Methylated

Andres Alguacil, Franco Scalambra, Antonio Romerosa, Andreia Bento-Oliveira, Fernanda Marques, Ines Maximiano, Rodrigo F. M. de Almeida, Ana Isabel Tomaz, and Andreia Valente
 
Published 28 Sept 2023
 
...Research efforts targeted to obtain alternatives to Pt(II) compounds have led to the development of new complexes containing metals that adopt different coordination geometries concerning the strictly square planar of Pt(II) and Pd(II). Among the transition metals that meet this requirement, ruthenium is one of the most promising [10–12]. Several ruthenium-based compounds have shown outstanding encouraging results such as Ru(III) complexes KP1019 (replaced by NKP1339/IT-139) and NAMI-A, which entered phases I and II of clinical trials, respectively [12]. Other examples are the Ru(II) complex TLD1433, which was evaluated in phase II [13, 14], and the compounds of the family of RAPTAs, which were tested in preclinical trials [15–17]. This latter group of complexes exhibits a Ru-(η6-arene) scaffold and 1,3,5-triaza-7-phosphaadamantane (PTA, 1) together with two chlorides (Figure 1) [18]. The combination of ligands and their arrangement around the metal provides a stable platform with adequate hydrosolubility, stabilizing the Ru(II) oxidation state [19]....
<< Previous
Bullboard Posts
Next >>